Canada’s national pharmacare program seems to be in a state of uncertainty, as the federal health minister has stated that Ottawa is not engaging in discussions with the remaining provinces and territories to finalize agreements. The recent budget did not allocate additional funds for expanding coverage nationwide, leading advocates to question the fate of the public drug plan.
Over a year ago, the Trudeau government passed the Canada Pharmacare Act, committing to establishing agreements with all provinces and territories to cover the costs of contraceptive and diabetes medications and devices. While four provinces and territories – B.C., Manitoba, P.E.I., and Yukon – signed deals with Ottawa before the federal election, no new agreements have been announced since then. Health Minister Marjorie Michel mentioned that her department is not actively pursuing discussions for new agreements.
CBC News reached out to the remaining provinces and territories to inquire about ongoing negotiations with Ottawa. Ontario did not provide a response, while Saskatchewan and New Brunswick expressed readiness to engage with Ottawa. Quebec and Alberta stated they are awaiting further communication from the federal government. Alberta also expressed concerns about the program’s long-term sustainability and desires more control over covered medications.
Despite some provinces expressing interest in signing agreements under the original framework, Nova Scotia indicated a desire to restart talks five months ago but has yet to receive a response from the federal government.
The absence of new funds in the recent budget has raised concerns among pharmacare advocates, who point out that existing agreements already consume a significant portion of the allocated budget. This situation casts doubt on the government’s commitment to expanding pharmacare coverage. Only about 17% of Canadians are currently covered by the pharmacare deals, leaving a substantial portion of the population without adequate access to essential medications.
The federal NDP has also voiced concerns over the lack of clarity and action from the government regarding pharmacare. The party emphasizes the importance of fulfilling commitments made under the confidence-and-supply agreement. The absence of additional funding in the budget raises questions about the government’s dedication to implementing a comprehensive pharmacare program accessible to all Canadians.